#codebreak200 search results
🎆🚨Out in @TheLancet, the final primary analysis of ph3 #codebreak200: #sotorasib significantly improved PFS and QoL over docetaxel in #NSCLC patients pre-treated with chemo/IO; underpowered for OS. Humbled to have offered this option to our patients-kudos to all contributors
#CodeBreaK200 study for pts with #KRASG12C-mut platinum/IO pretreated #NSCLC 🎯Sotorasib (oral KRASG12C inhibitor) showed superiority over docetaxel! ✅1y-PFS: 24.8 vs 10.1% (HR=0.66; P=0.002) ✅ORR: 28.1 vs 13.2% ⬇️grade≥3 TRAEs Congrats @MLJohnsonMD2 & team! #ESMO22 @OncoAlert
The Recent #Codebreak200 #Sotorasib #Lumikras With 1.1 mo PFS, 0.0 mo OS, 15k a month is a failure of Oncology The trial is even worse than that You won't believe it It is not even a randomized trial @FDAOncology may even veto it Full video coming: youtu.be/UNMwRp8XHw4
ESMO22 | @galetta2 su #CodeBreaK200: #sotorasib vs docetaxel nei pazienti con #NSCLC KRAS G12C #lcsm @myESMO
Check out these expert insights on #CodeBreaK200 🔍 from #ESMO2022, powered by Opus Strategy. For further analysis and key takeaways, click here ➡️ bit.ly/3qQBaFz #onctwitter #oncology #medtwitter #cancer
#ICI 後すぐに #KRAS 阻害剤へスイッチすることで重篤な肝毒性の懸念あり？！ #CodeBreaK200 とフランスのリアルワールド、２つの独立した報告で類似の傾向が示唆された。 生物学的な機序は依然として不明 前向き試験での検証余地あり #再発・進行期 #CodeBreaK
Results of the phase 3 #CodeBreak200 trail finds that sotorasib increased PFS compared with docetaxel in those with #KRASG12C+ advanced #NSCLC 💊🫁 Read the full study in @TheLancet by Adrianus Johannes de Langen, @LuisPaz_Ares and colleagues! ➡️ bit.ly/3DZzhNL
#Sotorasib #CPCNP #CodeBreak200 #ScienceLink Sotorasib demostró superioridad sobre la terapia estándar, docetaxel bit.ly/3wIHvX5
Great thread about our new paper #CodeBreak200 #sotorasib
Our new paper is out @VKprasadlab 2022 ! We analysed the confirmatory trial of sotorasib (1st KRAS inhibitor) in pts w/ lung cancer. Are the data enough for REGULAR authorization? @Swissmedic_ @EMA_News @FDAOncology ? Spoiler: WORSE survival not excluded w/ sotorasib 🛑 🧵👇
My full video on #CodeBreak200 #sotorasib is out now PFS of 1.1 month with 17%!!! early differential censoring OS - null I bet @FDAOncology will have to treat it as they did Quizartinib youtu.be/UNMwRp8XHw4
youtube.com
YouTube
CodeBreak 200 | Sotorasib | A Negligent trial that violated randomi...
🔬 ASCO 2023 Lung Cancer 🔬 ➡️ How were the molecularly-defined subsets of KRAS G12C-mutated advanced NSCLC biomarker subgroup analyses of #CodeBreaK200, and what specific biomarkers were evaluated? 🔗 oncologytube.com/video/42049/bi… @FSkoulidis @MDAndersonNews #NSCLC #ASCO23
#Sotorasib #CPCNP #CodeBreak200 #CoberturaESMO2022 #ScienceLink El resultado de supervivencia libre de progresión fue consistente en los subgrupos preespecificados. bit.ly/3eBBCok
The FDA is having a field day WRT bias in the #CodeBreaK200 study at #ODAC…LOLTA
CODE-Breaking data via @Amgen press release #CodeBreak200 Ph 3 sotorasib vs docetaxel in 2nd line setting met its PFS -primary endpoint N=345 👉KrasG12C found in 13% of NSCLC 👉Universal #biomakertesting needed to identify pts early #lcsm amgen.com/newsroom/press…
3. #CodeBreak200: Ph 3, 2L NSCLC with mKRAS G12c, sotorasib vs docetaxel @MLJohnsonMD2 - 12mos PFS 24.8% vs. 10.1% - mPFS was 5.6mos vs. 4.5 months - No OS benefit but fewer Gr≥3 TRAEs w/ sotorasib - Sotorasib was approved in May 2021. 5/9
#CodeBreak200 It is a dilemma. I definitely think the experience for most pts I have treated is better w #sotorasib vs docetaxel 2nd line but the survival advantage is not there. We need better KRASG12C drugs or combos. #lcsm #ESMO22
As was pointed out at the meeting, it is better to go for OS than PFS, as that endpoint is less prone to the issues identified in #CodeBreaK200…LOLTA
As was pointed out at the meeting, it is better to go for OS than PFS, as that endpoint is less prone to the issues identified in #CodeBreaK200…LOLTA
The FDA is having a field day WRT bias in the #CodeBreaK200 study at #ODAC…LOLTA
🔬 ASCO 2023 Lung Cancer 🔬 ➡️ How were the molecularly-defined subsets of KRAS G12C-mutated advanced NSCLC biomarker subgroup analyses of #CodeBreaK200, and what specific biomarkers were evaluated? 🔗 oncologytube.com/video/42049/bi… @FSkoulidis @MDAndersonNews #NSCLC #ASCO23
Results of the phase 3 #CodeBreak200 trail finds that sotorasib increased PFS compared with docetaxel in those with #KRASG12C+ advanced #NSCLC 💊🫁 Read the full study in @TheLancet by Adrianus Johannes de Langen, @LuisPaz_Ares and colleagues! ➡️ bit.ly/3DZzhNL
My full video on #CodeBreak200 #sotorasib is out now PFS of 1.1 month with 17%!!! early differential censoring OS - null I bet @FDAOncology will have to treat it as they did Quizartinib youtu.be/UNMwRp8XHw4
youtube.com
YouTube
CodeBreak 200 | Sotorasib | A Negligent trial that violated randomi...
The Recent #Codebreak200 #Sotorasib #Lumikras With 1.1 mo PFS, 0.0 mo OS, 15k a month is a failure of Oncology The trial is even worse than that You won't believe it It is not even a randomized trial @FDAOncology may even veto it Full video coming: youtu.be/UNMwRp8XHw4
🎆🚨Out in @TheLancet, the final primary analysis of ph3 #codebreak200: #sotorasib significantly improved PFS and QoL over docetaxel in #NSCLC patients pre-treated with chemo/IO; underpowered for OS. Humbled to have offered this option to our patients-kudos to all contributors
Great thread about our new paper #CodeBreak200 #sotorasib
Our new paper is out @VKprasadlab 2022 ! We analysed the confirmatory trial of sotorasib (1st KRAS inhibitor) in pts w/ lung cancer. Are the data enough for REGULAR authorization? @Swissmedic_ @EMA_News @FDAOncology ? Spoiler: WORSE survival not excluded w/ sotorasib 🛑 🧵👇
Check out these expert insights on #CodeBreaK200 🔍 from #ESMO2022, powered by Opus Strategy. For further analysis and key takeaways, click here ➡️ bit.ly/3qQBaFz #onctwitter #oncology #medtwitter #cancer
#Sotorasib #CPCNP #CodeBreak200 #CoberturaESMO2022 #ScienceLink El resultado de supervivencia libre de progresión fue consistente en los subgrupos preespecificados. bit.ly/3eBBCok
#CodeBreak200 It is a dilemma. I definitely think the experience for most pts I have treated is better w #sotorasib vs docetaxel 2nd line but the survival advantage is not there. We need better KRASG12C drugs or combos. #lcsm #ESMO22
ESMO22 | @galetta2 su #CodeBreaK200: #sotorasib vs docetaxel nei pazienti con #NSCLC KRAS G12C #lcsm @myESMO
3. #CodeBreak200: Ph 3, 2L NSCLC with mKRAS G12c, sotorasib vs docetaxel @MLJohnsonMD2 - 12mos PFS 24.8% vs. 10.1% - mPFS was 5.6mos vs. 4.5 months - No OS benefit but fewer Gr≥3 TRAEs w/ sotorasib - Sotorasib was approved in May 2021. 5/9
#CodeBreaK200 study for pts with #KRASG12C-mut platinum/IO pretreated #NSCLC 🎯Sotorasib (oral KRASG12C inhibitor) showed superiority over docetaxel! ✅1y-PFS: 24.8 vs 10.1% (HR=0.66; P=0.002) ✅ORR: 28.1 vs 13.2% ⬇️grade≥3 TRAEs Congrats @MLJohnsonMD2 & team! #ESMO22 @OncoAlert
#Sotorasib #CPCNP #CodeBreak200 #ScienceLink Sotorasib demostró superioridad sobre la terapia estándar, docetaxel bit.ly/3wIHvX5
CODE-Breaking data via @Amgen press release #CodeBreak200 Ph 3 sotorasib vs docetaxel in 2nd line setting met its PFS -primary endpoint N=345 👉KrasG12C found in 13% of NSCLC 👉Universal #biomakertesting needed to identify pts early #lcsm amgen.com/newsroom/press…
🎆🚨Out in @TheLancet, the final primary analysis of ph3 #codebreak200: #sotorasib significantly improved PFS and QoL over docetaxel in #NSCLC patients pre-treated with chemo/IO; underpowered for OS. Humbled to have offered this option to our patients-kudos to all contributors
#ICI 後すぐに #KRAS 阻害剤へスイッチすることで重篤な肝毒性の懸念あり？！ #CodeBreaK200 とフランスのリアルワールド、２つの独立した報告で類似の傾向が示唆された。 生物学的な機序は依然として不明 前向き試験での検証余地あり #再発・進行期 #CodeBreaK
#CodeBreaK200 study for pts with #KRASG12C-mut platinum/IO pretreated #NSCLC 🎯Sotorasib (oral KRASG12C inhibitor) showed superiority over docetaxel! ✅1y-PFS: 24.8 vs 10.1% (HR=0.66; P=0.002) ✅ORR: 28.1 vs 13.2% ⬇️grade≥3 TRAEs Congrats @MLJohnsonMD2 & team! #ESMO22 @OncoAlert
Results of the phase 3 #CodeBreak200 trail finds that sotorasib increased PFS compared with docetaxel in those with #KRASG12C+ advanced #NSCLC 💊🫁 Read the full study in @TheLancet by Adrianus Johannes de Langen, @LuisPaz_Ares and colleagues! ➡️ bit.ly/3DZzhNL
#Sotorasib #CPCNP #CodeBreak200 #ScienceLink Sotorasib demostró superioridad sobre la terapia estándar, docetaxel bit.ly/3wIHvX5
#Sotorasib #CPCNP #CodeBreak200 #CoberturaESMO2022 #ScienceLink El resultado de supervivencia libre de progresión fue consistente en los subgrupos preespecificados. bit.ly/3eBBCok
🔬 ASCO 2023 Lung Cancer 🔬 ➡️ How were the molecularly-defined subsets of KRAS G12C-mutated advanced NSCLC biomarker subgroup analyses of #CodeBreaK200, and what specific biomarkers were evaluated? 🔗 oncologytube.com/video/42049/bi… @FSkoulidis @MDAndersonNews #NSCLC #ASCO23
Something went wrong.
Something went wrong.
United States Trends
- 1. Good Monday 28.2K posts
- 2. TOP CALL 3,805 posts
- 3. AI Alert 1,421 posts
- 4. Market Focus 2,557 posts
- 5. #centralwOrldXmasXFreenBecky 562K posts
- 6. SAROCHA REBECCA DISNEY AT CTW 578K posts
- 7. #MondayMotivation 7,611 posts
- 8. #BaddiesUSA 66.2K posts
- 9. #LingOrmDiorAmbassador 296K posts
- 10. NAMJOON 56.6K posts
- 11. Check Analyze N/A
- 12. Token Signal 1,890 posts
- 13. Rams 30.6K posts
- 14. #LAShortnSweet 24.4K posts
- 15. DOGE 184K posts
- 16. Chip Kelly 9,348 posts
- 17. Vin Diesel 1,577 posts
- 18. Stacey 23.9K posts
- 19. Scotty 10.5K posts
- 20. Monad 115K posts